首页> 外文OA文献 >Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

【2h】

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

机译：局部Trka激酶抑制剂CT327是一种有效的新疗法，用于治疗瘙痒症，由于牛皮癣：实验研究的结果，CT327在牛皮癣患者的2B期临床试验中的实验研究和CT327的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D Roblin; G Yosipovitch; B Boyce; J Robinson; J Sandy; V Mainero; R Wickramasinghe; U Anand; P Anand;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis [J] . Bissonnette Robert, Pariser David M., Wasel Norman R., Journal of the American Academy of Dermatology . 2016,第1期

机译：口服磷酸二酯酶4抑制剂Apremilast在治疗掌足型牛皮癣中的应用：II期PSOR-005和III期疗效和安全性试验的合并分析结果，评估了Apremilast对银屑病（ESTEEM）在中度患者中的临床试验的效果重度牛皮癣
2. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis [J] . Bissonnette Robert, Pariser David M., Wasel Norman R., Journal of the American Academy of Dermatology . 2016,第1期

机译：Apremilast，一种口服磷酸二酯酶-4抑制剂，治疗棕榈术牛皮癣：来自II期PSOR-005和III期疗效和安全试验的汇总分析的结果评估中度患者患者的牛皮癣（尊重）临床试验的影响对严重的牛皮癣
3. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis [J] . PortsW.C., KhanS., LanS., British Journal of Dermatology . 2013,第1期

机译：局部Janus激酶抑制剂托法替尼治疗慢性斑块状牛皮癣的随机2a期疗效和安全性试验
4. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis [O] . WC Ports, S Khan, S Lan, -1

机译：局部Janus激酶抑制剂托法替尼治疗慢性斑块状牛皮癣的随机2a期疗效和安全性试验
5. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis [O] . Bissonnette Robert, Pariser David M., Wasel Norman R., 2016

机译：口服磷酸二酯酶-4抑制剂Apremilast在治疗掌足型牛皮癣中的应用：II期PSOR-005和III期有效性和安全性试验的合并分析结果，评估了Apremilast对银屑病（ESTEEM）在中度患者中的临床试验的效果重度牛皮癣

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

著录项

引文网络

相似文献

相关主题

期刊订阅